Skip to content

Search

IgE and T-cell responses to house dust mite allergen components

Recent studies with synthetic peptides representing allergens and non-allergenic house dust mite proteins now offer new research avenues on HDM induced immune responses

Blueprint for the House Dust Mite

The completeness of the coverage of a genome assembly is a critical starting point for all genomic projects so considerable attention is given to the sequencing metrics, which showed high indicators of success.

Early nutrition and its effect on allergy development

Nutrition is one of the most easily modifiable environmental factors during early life that may play a role in allergic disease prevention.

The cat lipocalin Fel d 7 and its cross-reactivity with the dog lipocalin Can f 1

Fel d 7 is a common allergen in a Swedish cat-sensitized population that cross-reacts with Can f 1

House Dust Mite Allergens: New Discoveries and Relevance to the Allergic Patient

Recent findings on house dust allergens and their contribution to knowledge that will significantly impact current and future allergy treatments are appraised

Distinguishing benign from pathologic TH2 immunity in atopic children

In addition to its role in blocking TH2 effector activation in the late-phase allergic response, IL-10 is a known IgG1 switch factor

Western environment/lifestyle is associated with increased genome methylation and decreased gene expression in Chinese immigrants living in Australia

Chinese immigrants living in Australia for a longer period of time have increased overall genome methylation and decreased overall gene expression

Barriers and Considerations for Diagnosing Rare Diseases in Indigenous Populations

Advances in omics and specifically genomic technologies are increasingly transforming rare disease diagnosis. However, the benefits of these advances are disproportionately experienced within and between populations, with Indigenous populations frequently experiencing diagnostic and therapeutic inequities. The International Rare Disease Research Consortium (IRDiRC) multi-stakeholder partnership has been advancing toward the vision of all people living with a rare disease receiving an accurate diagnosis, care, and available therapy within 1 year of coming to medical attention. In order to further progress toward this vision, IRDiRC has created a taskforce to explore the access barriers to diagnosis of rare genetic diseases faced by Indigenous peoples, with a view of developing recommendations to overcome them.

Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life

Neonates have heightened susceptibility to infections. The biological mechanisms are incompletely understood but thought to be related to age-specific adaptations in immunity due to resource constraints during immune system development and growth. We present here an extended analysis of our proteomics study of peripheral blood-plasma from a study of healthy full-term newborns delivered vaginally, collected at the day of birth and on day of life (DOL) 1, 3, or 7, to cover the first week of life. The plasma proteome was characterized by LC-MS using our established 96-well plate format plasma proteomics platform.

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C

Safe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.